Solid Biosciences Inc. (SLDB): R&D Expense
$140.32M
Year ended 2025-12-31
$167.40M
Trailing 12 months to 2026-06-30
+21.4%
3-year compound annual growth
+16.7%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $140.32M | +45.5% | 2026-03-19, From 2025-01-01 |
| 2024-12-31 | $96.43M | +25.9% | 2026-03-19, From 2024-01-01 |
| 2023-12-31 | $76.56M | -2.4% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $78.42M | +33.5% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $58.74M | -9.5% | 2024-03-13, From 2021-01-01 |
| 2020-12-31 | $64.88M | -31.5% | 2023-03-23, From 2020-01-01 |
| 2019-12-31 | $94.74M | +63.4% | 2022-03-14, From 2019-01-01 |
| 2018-12-31 | $57.97M | +45.3% | 2021-03-15, From 2018-01-01 |
| 2017-12-31 | $39.91M | +98.4% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $20.12M | n/a | 2019-03-13, From 2016-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | 2025-12-31 | $140.32M | +45.5% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $116.68M | +30.6% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $114.15M | +6.3% |
| Agenus Inc (AGEN) | 2025-12-31 | $79.34M | -49.0% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $95.67M | -10.8% |
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $94.48M | +146.6% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $129.62M | +8.5% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $94.43M | -13.5% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $149.06M | +17.8% |
Compare SLDB, DBVT, TCRX, AGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗